The World Health Organization announced today that it will temporarily omit the anti-malaria drug - hydroxychloroquine - from its global study on the treatment of Covid-19.
The WHO stated that they are doing this because their experts have to review all available evidence to date.
US President Donald Trump previously stated that he takes the drug to relieve symptoms in case he is infected with the coronavirus, although its effectiveness against the infection has not been proven.
WHO Director General Tedros Adhanom Ghebreyesus said today that based on the text in the scientific journal Lancet, it was decided to "temporarily pause" the research of that drug in their trial study dealing with the treatment of the disease caused by the coronavirus.
The paper, published last week, said people who take hydroxychloroquine have a higher risk of death and heart problems than those who don't.
"This concern relates to the use of hydroxychloroquine and chloroquine to treat Covid-19," he said, adding that those drugs are still acceptable for treating malaria or autoimmune diseases.
Other treatments for Covid-19 include the drug remdesivir and combination therapy for HIV.
Hydroxychloroquine can have serious side effects in some patients, and so far there is no evidence that it helps against the new coronavirus.
Bonus video: